A recent study by Su and colleagues reported the development of cationic liposomes loaded with peptide vaccine and indoleamine-2,3-dioxygenase (IDO) inhibitor for combinatorial melanoma therapy [334]. The gene discussed is IDO1; the disease is melanoma.